| 6-months’ follow-up |  | 15-months’ follow-up | ||||
---|---|---|---|---|---|---|---|
CC (n = 369) | TAU (n = 37) | P | Effect size | CC (n = 369) | TAU (n = 37) | P | |
Primary outcome | |||||||
 BAI | 11.5 (10.6–12.4) | 14.6 (9.9–19.3) | 0.206 | 0.33 | 11.0 (10.2–11.9) | 12.7 (10.2–15.3) | 0.209 |
Secondary outcomes | |||||||
 BDI-II | 9.2 (8.3–10.1) | 11.3 (6.3–16.3) | 0.418 |  | 9.1 (8.3–9.9) | 10.9 (7.7–14.0) | 0.295 |
 SCL-90-Ra | 48.6 (43.8–53.3) | 64.9 (40.5–89.4) | 0.200 |  | 47.4 (42.6–52.0) | 42.7 (23.1–62.2) | 0.657 |
 GAF | 72.5 (70.9–74.1) | 72.9 (68.8–77.0) | 0.855 |  | 74.8 (73.3–76.3) | 80.3 (71.6–89.0) | 0.224 |
Explorative outcomes | |||||||
 The Diagnostic Apathia Scale | 2.5 (2.2–2.8) | 2.4 (1.3–3.5) | 0.843 |  | 2.1 (1.9–2.4) | 2.1 (1.0–3.3) | 0.961 |
 PSP | 72.6 (71.2–74.1) | 72.7 (69.3–76.2) | 0.951 |  | 75.3 (73.7–76.9) | 82.1 (65.5–98.8) | 0.417 |
 SDS | 6.2 (5.4–7.0) | 7.1 (4.6–9.7) | 0.485 |  | 5.5 (4.6–6.3) | 7.1 (4.5–9.7) | 0.243 |
 WHO-5 | 59.1 (56.7–61.4) | 59.2 (48.9–69.3) | 0.995 |  | 61.7 (59.0–64.5) | 53.0 (37.8–68.2) | 0.271 |
 Personal Controlb | 23.3 (22.8–23.8) | 22.2 (20.2–24.2) | 0.282 |  | 19.9 (19.6–20.2) | 20.3 (19.3–21.2) | 0.465 |
 Control/Manage Depressionc | 7.1 (6.9–7.3) | 6.0 (4.9–7.0) | 0.031 |  | 7.2 (6.9–7.4) | 7.1 (6.3–7.9) | 0.885 |
 Obtain Help from Community, Family, Friendsc | 7.2 (6.9–7.4) | 6.9 (5.8–8.0) | 0.637 |  | 7.4 (7.2–7.6) | 7.3 (6.6–8.1) | 0.848 |
 EQ-5D-3 L | 0.84 (0.82–0.86) | 0.78 (0.67–0.90) | 0.294 |  | 0.8 (0.8–0.9) | 0.9 (0.8–0.9) | 0.536 |
 PRISEd | 15.0 (13.0–16.9) | 14.0 (5.3–22.7) | 0.828 |  | 12.1 (9.9–14.3) | 15.4 (0.8–30.6) | 0.662 |
 Remission, % | 45.7 (40.1–51.2) | 39.2 (22.3–56.2) | 0.481 |  | 49.0 (43.2–54.9) | 42.3 (24.6–60.0) | 0.442 |
 INSPIRE-S | 74.0 (70.7–77.3) | 67.7 (50.0–85.4) | 0.488 |  | – | – |  |
 INSPIRE-R | 85.8 (83.6–88.0) | 82.4 (69.7–95.1) | 0.604 |  | – | – |  |
 CSQ-8 | 26.7 (26.2–27.4) | 23.9 (17.5–30.2) | 0.368 |  | – | – |  |